Cardiovascular safety of tocilizumab therapy: results of the ENTRACTE Clinical Trial
Authors:
Heřman Mann
Authors‘ workplace:
Revmatologická klinika 1. LF UK a Revmatologický ústav, Praha
Published in:
AtheroRev 2018; 3(2): 101-105
Category:
clinical studies
Overview
Rheumatoid arthritis is associated with an increased risk of cardiovascular disease, due to chronic inflammation in addition to other typical risk factors. A so-called lipid paradox has been described in patients with rheumatoid arthritis, a situation in which inflammation induces a decrease and successful anti-inflammatory treatment is associated with an increase in serum lipid levels. Suppression of inflammatory activity by methotrexate or biological agents leads to a reduction of cardiovascular disease risk. During treatment with tocilizumab, there is a more significant increase in cholesterol levels compared with treatment with tumor necrosis factor-blockers. Changes in the lipid levels usually occur within the first weeks of treatment with tocilizumab and stabilize thereafter. Analysis of available data and the results of ENTRACTE trial failed to show an increased risk of cardiovascular events associated with tocilizumab compared to other biologics.
Key words:
cardiovascular risk, lipidogram, rheumatoid arthritis, tocilizumab
Sources
- Šenolt L, Mann H. Závada J et al. Doporučení České revmatologické společnosti pro farmakologickou léčbu revmatoidní artritidy 2017. Čes Revmatol 2017; 25(1): 8–24.
- Choy E, Ganeshalingam K, Semb AG et al. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology (Oxford) 2014; 53(12) :2143–2154. Dostupné z DOI: <http://dx.doi.org/10.1093/rheumatology/keu224>.
- Crowson CS, Rollefstad S, Ikdahl E et al. Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Ann Rheum Dis 2018;77(1):48–54. Dostupné z DOI: <http://dx.doi.org/10.1136/annrheumdis-2017–211735>.
- Myasoedova E, Crowson CS, Kremers HM et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 2011; 70(3): 482–487. Dostupné z DOI: <http://dx.doi.org/10.1136/ard.2010.135871>.
- Peters MJ, Symmons DP, McCarey D et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69(2): 325–331. Dostupné z DOI: <http://dx.doi.org/10.1136/ard.2009.113696>.
- Crowson CS, Gabriel SE, Semb AG et al. Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries. Rheumatology (Oxford) 2017;56(7): 1102–1110. Dostupné z DOI: <http://dx.doi.org/10.1093/rheumatology/kex038>.
- Roubille C, Richer V, Starnino T et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2015; 74(3): 480–489. Dostupné z DOI: <http://dx.doi.org/10.1136/annrheumdis-2014–206624>.
- Greenberg JD, Kremer JM, Curtis JR et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70(4): 576–582. Dostupné z DOI: <http://dx.doi.org/10.1136/ard.2010.129916>.
- McInnes IB, Thompson L, Giles JT et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis 2015; 74(4): 694–702. Dostupné z DOI: <http://dx.doi.org/10.1136/annrheumdis-2013–204345>.
- Gabay C, McInnes IB, Kavanaugh A et al. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. Ann Rheum Dis 2016; 75(10): 1806–1812. Dostupné z DOI: <http://dx.doi.org/10.1136/annrheumdis-2015–207872>.
- Kim SC, Solomon DH, Rogers JR et al. Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a multi-database cohort study. Arthritis Rheumatol 2017; 69(6): 1154–1164. Dostupné z DOI: <http://dx.doi.org/10.1002/art.40084>.
- Kim SC, Solomon DH, Rogers JR et al. No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: A multi-database cohort study. Semin Arthritis Rheum 2018. pii: S0049–0172(17)30810–7. Dostupné z DOI: <http://dx.doi.org/10.1016/j.semarthrit.2018.03.012>.
- Giles JT, Sattar N, Gabriel SE et al. Comparative cardiovascular safety of tocilizumab vs etanercept in rheumatoid arthritis: results of a randomized, parallel-group, multicenter, noninferiority, phase 4 clinical trial. Arthritis Rheumatol 2016; 68(Suppl 10): 4357–4359. Dostupné z DOI: <http://acrabstracts.org/abstract/comparative-cardiovascular-safety-of-tocilizumab-vs-etanercept-in-rheumatoid-arthritis-results-of-a-randomized-parallel-group-multicenter-noninferiority-phase-4-clinical-trial>.
Labels
Angiology Diabetology Internal medicine Cardiology General practitioner for adultsArticle was published in
Athero Review
2018 Issue 2
Most read in this issue
- What a rheumatologist should know about statins and their side effects
- Detection of aortic calcifications within the assessment of lateral densitometric scans
- Familial chylomicronemia: pathogenesis, clinical manifestations and case study
- The impact of rheumatic diseases on cardiovascular risk and lipidogram